



To the Editor: Vervaet et al.1 demonstrated the crystal-
handling mechanism in rats after ethylene glycol administra-
tion. They revealed that intratubular crystal formation
appeared on day 2, and nephrocalcinosis was cleared by
epithelial overgrowth of adherent crystals from day 5 to day
10, following translocation to the interstitium.1 These ﬁndings
are helpful in understanding why both intratubular and
interstitial nephrocalcinosis was found in our patient who
died of pseudo-Bartter’s syndrome after 8 days’ intake of diet
pills.2 Furosemide inhibits Naþ–Kþ–2Cl cotransporters in
the thick ascending limb of the loop of Henle (TAL) and
increases intraluminal calcium concentration. Hence, crystals
have been believed to form downstream of TAL. However, we
observed nephrocalcinosis around the inﬂection point of the
thin descending limb of the loop of Henle (DTL),2 upstream
of TAL. Interestingly, NaPi-IIa in the proximal tubule and
Ca2þ -ATPase in the thin limb were decreased in our patient
compared with the control (Figure 1), which may have
increased intraluminal calcium and phosphate levels at the
DTL. As angiotensin II inhibits Ca2þ -ATPase,3 enhanced
renin–angiotensin systems could have a role in nephrocalci-
nosis in pseudo-Bartter’s syndrome.
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The Authors Reply: We thank Tojo et al.1 for their interest
in our work.2 It is scientiﬁcally rewarding to read that our
ﬁndings contribute to (1) the increasing awareness that
identiﬁcation of the actual histological site of resident
renal crystals in conditions or pathologies with associated
nephrocalcinosis is important in understanding the develop-
ment and course of renal crystal deposition, and (2) the
understanding that the site at which crystals are found might
not necessarily be the original place of crystal formation.
Furthermore, although no clear-cut epithelial overgrowth
structures could be observed on the images in the case report
on the pseudo-Bartter’s syndrome3 nor were reported in the
authors’ letter to the editor,1 the observation of multi-
nucleated giant cells associated with interstitial crystals3 is in
accordance with the observations of de Bruijn et al.4 and
further corroborates the existence of a default active renal
crystal-clearing mechanism.2 With respect to intratubular
crystal formation, it is clear that the risk of crystallization
along the nephron is highest at points where ion and
water transport are uncoupled: that is, the loop of Henle and
the collecting duct. However, the risk proﬁle can extend
upstream and the level of crystallization can increase owing to
either insufﬁcient water intake or increased ﬁltered loads of
crystal ions, which are known to depend on diurnal variation,
intake of diets rich in crystal constituents, and the
postprandial state. Alternatively, as illustrated by the authors’
report on pseudo-Bartter’s syndrome, pathological conditions
or drug abuse affecting proper tubular calcium and phosphate
handling at the molecular level may greatly inﬂuence both the
location and the probability of crystallization along the
nephron.
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Figure 1 | Immunostaining and western blot for NaPi-IIa and
Ca2þ -ATPase. Bar¼ 50mm.
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